{"transactions":[{"id":737960,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38219,"kind":"person","name":"Gupta Shalabh K.","position":1,"cik":"0001864917","reported_name":"Gupta Shalabh K.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Units","published_at":"2026-06-15T21:24:50.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":762200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. 105,861 shares vest upon grant and 21,172 shares vest over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. 105,861 shares vest upon grant and 21,172 shares vest over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":762200,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":762200},"source":{"system":"sec-edgar","filing":"0001213900-26-068922","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864917/000121390026068922/ownership.xml","form_type":"4/A","original_submission_date":"2026-05-21"}},{"id":768143,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38219,"kind":"person","name":"Gupta Shalabh K.","position":1,"cik":"0001864917","reported_name":"Gupta Shalabh K.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Units","published_at":"2026-05-21T20:30:27.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":762200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":762200,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":762200},"source":{"system":"sec-edgar","filing":"0001213900-26-060080","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864917/000121390026060080/ownership.xml","form_type":"4"}},{"id":1079231,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38219,"kind":"person","name":"Gupta Shalabh K.","position":1,"cik":"0001864917","reported_name":"Gupta Shalabh K.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Options","published_at":"2025-07-30T20:30:11.000Z","date":"2025-07-28","kind":"grant","planned":false,"acquired":true,"shares":325000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"81,250 of the stock options vest on July 28, 2026 and 1/36th of the remaining options vest at the end of each successive month thereafter."}],"balance_after":968951,"derivative":{"exercise_price":4.71,"expiration_date":"2035-07-28","underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001213900-25-069303","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864917/000121390025069303/ownership.xml","form_type":"4"}},{"id":1433875,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38219,"kind":"person","name":"Gupta Shalabh K.","position":1,"cik":"0001864917","reported_name":"Gupta Shalabh K.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Options","published_at":"2024-08-14T20:15:17.000Z","date":"2024-08-12","kind":"grant","planned":false,"acquired":true,"shares":232868,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"58,217 of the stock options vest on August 12, 2025 and 1/36th of the remaining options vest at the end of each successive month thereafter."}],"balance_after":6439505,"derivative":{"exercise_price":0.34,"expiration_date":"2034-08-12","underlying":"Common Stock","underlying_shares":232868},"source":{"system":"sec-edgar","filing":"0001213900-24-069034","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864917/000121390024069034/ownership.xml","form_type":"4"}},{"id":1540135,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38219,"kind":"person","name":"Gupta Shalabh K.","position":1,"cik":"0001864917","reported_name":"Gupta Shalabh K.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Stock Options","published_at":"2024-04-17T20:31:09.000Z","date":"2024-04-15","kind":"grant","planned":false,"acquired":true,"shares":1319583,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"329,896 of the stock options vest on the first anniversary of the date of grant and 1/36th of the remaining options vest at the end of each successive month thereafter."}],"balance_after":6206637,"derivative":{"exercise_price":1.14,"expiration_date":"2034-04-15","underlying":"Common Stock","underlying_shares":1319583},"source":{"system":"sec-edgar","filing":"0001213900-24-033828","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864917/000121390024033828/ownership.xml","form_type":"4"}},{"id":1793178,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38219,"kind":"person","name":"Gupta Shalabh K.","position":1,"cik":"0001864917","reported_name":"Gupta Shalabh K.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Options","published_at":"2023-08-30T20:47:02.000Z","date":"2023-08-28","kind":"grant","planned":false,"acquired":true,"shares":4684775,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1,171,194 of the stock options vest on March 6, 2024 and 1/36th of the remaining options vest at the end of each successive month thereafter."}],"balance_after":4988798,"derivative":{"exercise_price":0.75,"expiration_date":"2033-08-28","underlying":"Common Stock","underlying_shares":4684775},"source":{"system":"sec-edgar","filing":"0001213900-23-072251","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864917/000121390023072251/ownership.xml","form_type":"4"}},{"id":1830384,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38219,"kind":"person","name":"Gupta Shalabh K.","position":1,"cik":"0001864917","reported_name":"Gupta Shalabh K.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Warrant (right to buy)","published_at":"2023-07-13T22:10:25.000Z","date":"2023-07-11","kind":"exercise","planned":false,"acquired":true,"shares":115275,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Tranche C Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Company's public disclosure of financial results for four (4) quarters of commercial sales of Renazorb following receipt of Transitional Drug Add-On Payment Adjustment approval for Renazorb, commencing with the first quarter in which the Company receives revenue from Centers for Medicare and Medicaid Services for Renazorb under the Transitional Drug Add-On Payment Adjustment."}],"balance_after":115275,"derivative":{"exercise_price":0.74,"exercise_date":"2023-07-11","underlying":"Series A-5 Convertible Preferred Stock","underlying_shares":115275},"source":{"system":"sec-edgar","filing":"0001213900-23-056848","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1864917/000121390023056848/ownership.xml","form_type":"4"}},{"id":1830383,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38219,"kind":"person","name":"Gupta Shalabh K.","position":1,"cik":"0001864917","reported_name":"Gupta Shalabh K.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Warrant (right to buy)","published_at":"2023-07-13T22:10:25.000Z","date":"2023-07-11","kind":"exercise","planned":false,"acquired":true,"shares":72047,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Tranche B Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Company's announcement of receipt of Transitional Drug Add-On Payment Adjustment approval for Renazorb."}],"balance_after":72047,"derivative":{"exercise_price":0.59,"exercise_date":"2023-07-11","underlying":"Series A-4 Convertible Preferred Stock","underlying_shares":72047},"source":{"system":"sec-edgar","filing":"0001213900-23-056848","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1864917/000121390023056848/ownership.xml","form_type":"4"}},{"id":1830382,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38219,"kind":"person","name":"Gupta Shalabh K.","position":1,"cik":"0001864917","reported_name":"Gupta Shalabh K.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Warrant (right to buy","published_at":"2023-07-13T22:10:25.000Z","date":"2023-07-11","kind":"exercise","planned":false,"acquired":true,"shares":79252,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Tranche A Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Issuer's announcement of receipt of FDA approval for Renazorb."}],"balance_after":79252,"derivative":{"exercise_price":0.54,"exercise_date":"2023-07-11","underlying":"Series A-3 Convertible Preferred Stock","underlying_shares":79252},"source":{"system":"sec-edgar","filing":"0001213900-23-056848","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864917/000121390023056848/ownership.xml","form_type":"4"}},{"id":1830381,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38219,"kind":"person","name":"Gupta Shalabh K.","position":1,"cik":"0001864917","reported_name":"Gupta Shalabh K.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2023-07-13T22:10:25.000Z","date":"2023-07-11","kind":"exercise","planned":false,"acquired":false,"shares":50,"price":1000,"value":50000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 11, 2023, the shares of Series A-1 Convertible Preferred Stock automatically converted into units consisting of (1) 104,612 shares of common stock, (2) a Tranche A Warrant to purchase 79,252 shares of Series A-3 Convertible Preferred Stock, (3) a Tranche B Warrant to purchase 72,047 shares of Series A-4 Convertible Preferred Stock and (4) a Tranche C Warrant to purchase 115,275 shares of Series A-5 Convertible Preferred Stock. The shares of Series A-1 Convertible Preferred Stock had no expiration date prior to conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On July 11, 2023, the shares of Series A-1 Convertible Preferred Stock automatically converted into units consisting of (1) 104,612 shares of common stock, (2) a Tranche A Warrant to purchase 79,252 shares of Series A-3 Convertible Preferred Stock, (3) a Tranche B Warrant to purchase 72,047 shares of Series A-4 Convertible Preferred Stock and (4) a Tranche C Warrant to purchase 115,275 shares of Series A-5 Convertible Preferred Stock. The shares of Series A-1 Convertible Preferred Stock had no expiration date prior to conversion."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On July 11, 2023, the shares of Series A-1 Convertible Preferred Stock automatically converted into units consisting of (1) 104,612 shares of common stock, (2) a Tranche A Warrant to purchase 79,252 shares of Series A-3 Convertible Preferred Stock, (3) a Tranche B Warrant to purchase 72,047 shares of Series A-4 Convertible Preferred Stock and (4) a Tranche C Warrant to purchase 115,275 shares of Series A-5 Convertible Preferred Stock. The shares of Series A-1 Convertible Preferred Stock had no expiration date prior to conversion."}],"balance_after":0,"derivative":{"exercise_price":0.49,"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001213900-23-056848","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864917/000121390023056848/ownership.xml","form_type":"4"}},{"id":1830380,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38219,"kind":"person","name":"Gupta Shalabh K.","position":1,"cik":"0001864917","reported_name":"Gupta Shalabh K.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-07-13T22:10:25.000Z","date":"2023-07-11","kind":"exercise","planned":false,"acquired":true,"shares":104612,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share."}],"balance_after":2527449,"source":{"system":"sec-edgar","filing":"0001213900-23-056848","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864917/000121390023056848/ownership.xml","form_type":"4"}},{"id":1961251,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38219,"kind":"person","name":"Gupta Shalabh K.","position":1,"cik":"0001864917","reported_name":"Gupta Shalabh K.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Series A Convertible Preferred Stock","published_at":"2023-03-10T02:37:51.000Z","date":"2023-03-08","kind":"grant","acquired":true,"shares":50,"price":1000,"value":50000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Conversion Price of the Series A-1 Preferred Stock is subject to adjustment as set forth in that certain of Designation of Preferences, Rights and\nLimitations of the Series A Convertible Voting Preferred Stock attached as Exhibit 3.1 to the Issuer's Form 8-K filed with the Securities and Exchange\nCommission on March 6, 2023 (the \"Certificate of Designation\"). Capitalized terms that are used but not defined in this Form 4 have the meanings given to\nthem in the Certificate of Designation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of Series A-1 Convertible Preferred Stock are not convertible until the stockholders of the Issuer approve the Proposals. Additionally, on the Automatic Conversion Date, as set forth in the Certificate of Designation, each share of Series A-1 Preferred Stock shall automatically convert into a unit consisting of (1) shares of Common Stock (or shares of Series A-2 Preferred Stock) equal to the quotient of (A) the Liquidation Preference divided by (B) the Conversion Price, (2) a Tranche A Warrant, (3) a Tranche B Warrant and (4) a Tranche C Warrant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Series A-1 Convertible Preferred Stock have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Tranche A Warrants are exercisable for Series A-3 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche B Warrants are exercisable for Series A-4 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche C Warrants are exercisable for Series A-5 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. All shares of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock have no expiration date and are convertible into shares of Common Stock in accordance with the Certificate of Designation."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The shares of Series A-1 Convertible Preferred Stock are not convertible until the stockholders of the Issuer approve the Proposals. Additionally, on the Automatic Conversion Date, as set forth in the Certificate of Designation, each share of Series A-1 Preferred Stock shall automatically convert into a unit consisting of (1) shares of Common Stock (or shares of Series A-2 Preferred Stock) equal to the quotient of (A) the Liquidation Preference divided by (B) the Conversion Price, (2) a Tranche A Warrant, (3) a Tranche B Warrant and (4) a Tranche C Warrant."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F4","text":"The Tranche A Warrants are exercisable for Series A-3 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche B Warrants are exercisable for Series A-4 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche C Warrants are exercisable for Series A-5 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. All shares of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock have no expiration date and are convertible into shares of Common Stock in accordance with the Certificate of Designation."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The shares of Series A-1 Convertible Preferred Stock are not convertible until the stockholders of the Issuer approve the Proposals. Additionally, on the Automatic Conversion Date, as set forth in the Certificate of Designation, each share of Series A-1 Preferred Stock shall automatically convert into a unit consisting of (1) shares of Common Stock (or shares of Series A-2 Preferred Stock) equal to the quotient of (A) the Liquidation Preference divided by (B) the Conversion Price, (2) a Tranche A Warrant, (3) a Tranche B Warrant and (4) a Tranche C Warrant."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"The Tranche A Warrants are exercisable for Series A-3 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche B Warrants are exercisable for Series A-4 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche C Warrants are exercisable for Series A-5 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. All shares of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock have no expiration date and are convertible into shares of Common Stock in accordance with the Certificate of Designation."}],"balance_after":50,"derivative":{"exercise_price":0.4933,"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001213900-23-018970","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864917/000121390023018970/ownership.xml","form_type":"4"}},{"id":2105454,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38219,"kind":"person","name":"Gupta Shalabh K.","position":1,"cik":"0001864917","reported_name":"Gupta Shalabh K.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Options","published_at":"2022-11-23T13:00:17.000Z","date":"2022-11-21","kind":"grant","acquired":true,"shares":86000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"21,500 of the stock options vest on first anniversary of the date of grant and 1/36th of the remaining options vest at the end of each successive month thereafter."}],"balance_after":202279,"derivative":{"exercise_price":0.75,"expiration_date":"2032-11-21","underlying":"Common Stock","underlying_shares":86000},"source":{"system":"sec-edgar","filing":"0001213900-22-074721","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864917/000121390022074721/ownership.xml","form_type":"4"}},{"id":2625124,"issuer":{"id":6568,"kind":"organization","name":"Unicycive Therapeutics, Inc."},"owners":[{"id":38219,"kind":"person","name":"Gupta Shalabh K.","position":1,"cik":"0001864917","reported_name":"Gupta Shalabh K.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Options","published_at":"2021-07-26T20:15:32.000Z","date":"2021-07-15","kind":"grant","acquired":true,"shares":116279,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest equally over a period of three years from the date of grant."}],"balance_after":218023,"derivative":{"exercise_price":5,"expiration_date":"2031-07-15","underlying":"Common Stock","underlying_shares":116279},"source":{"system":"sec-edgar","filing":"0001213900-21-038633","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864917/000121390021038633/ownership.xml","form_type":"4"}}]}